Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel–Lindau Tumor Suppressor Protein (VHL)

Most ligands for the Von Hippel-Lindau tumor suppressor (VHL) bind at the HIF-1α binding site. Ligands that bind to allosteric sites on VHL could be highly valuable for the field of protein degradation, therefore, a covalent hit identification campaign was run targeting Cys77 on VHL. Hit <b>2</b> bound selectively to Cys77 on VHL and did not alkylate the reactive Cys89 on Elongin B. It showed time- and concentration-dependent labeling, with a <i>k</i> <sub>inact</sub>/<i>K</i> <sub>I</sub> of 0.30 M<sup>-1</sup> s<sup>-1</sup>, and does not affect binding at the HIF-1α site. This hit ligand was optimized to afford compound <b>15</b> which showed improved potency and labeling of VHL. An X-ray structure of a close analogue was determined revealing the compound binding in a shallow groove on the surface of VHL. These are the first small molecules that bind covalently to an allosteric site on VHL and provide a suitable starting point for further optimization.

Authors

Institutions

Publication Details

Journal
ACS Medicinal Chemistry Letters
Published
2025-03-19
DOI
https://doi.org/10.1021/acsmedchemlett.4c00582
Citations
2
Primary Topic
Protein Degradation and Inhibitors
Type
article
Field-Weighted Citation Impact
1.61
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel–Lindau Tumor Suppressor Protein (VHL)

Sylvain Demanze, C. R. Phillips, Sarah H. Hewitt, C. Truman et al.
2 citations
ACS Medicinal Chemistry Letters
Protein Degradation and Inhibitors
1.61
article

Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel–Lindau Tumor Suppressor Protein (VHL)

Sylvain Demanze, C. R. Phillips, Sarah H. Hewitt, C. Truman, Honglin Hao, Nancy Su, Lucia Fusani, Gavin W. Collie, Ganesh Kadamur, Yong Xu, Simon C. C. Lucas, Thomas E. Hadfield
article en
2 citations

Abstract

Most ligands for the Von Hippel-Lindau tumor suppressor (VHL) bind at the HIF-1α binding site. Ligands that bind to allosteric sites on VHL could be highly valuable for the field of protein degradation, therefore, a covalent hit identification campaign was run targeting Cys77 on VHL. Hit <b>2</b> bound selectively to Cys77 on VHL and did not alkylate the reactive Cys89 on Elongin B. It showed time- and concentration-dependent labeling, with a <i>k</i> <sub>inact</sub>/<i>K</i> <sub>I</sub> of 0.30 M<sup>-1</sup> s<sup>-1</sup>, and does not affect binding at the HIF-1α site. This hit ligand was optimized to afford compound <b>15</b> which showed improved potency and labeling of VHL. An X-ray structure of a close analogue was determined revealing the compound binding in a shallow groove on the surface of VHL. These are the first small molecules that bind covalently to an allosteric site on VHL and provide a suitable starting point for further optimization.

ACS Medicinal Chemistry LettersVol. 16(4)
Pharmaron (United Kingdom) (GB), AstraZeneca (Singapore) (SG), AstraZeneca (Poland) (PL), Institute of Medicinal Plant Development (CN), AstraZeneca (United States) (US), AstraZeneca (Germany) (DE)
Zero hunger
Openalex Percentile: Top 18%
Protein Degradation and Inhibitors
1.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.